KPL-387 not checked
Kiniksa Pharmaceuticals International, plc
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pericarditis (2 trials), Recurrent Pericarditis (2 trials), Pericarditis Acute, Heart Diseases
- Main trialPhase 2/3
- “This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.”In the company’s words, NCT07010159 on ClinicalTrials.gov
Other drugs for Pericarditis
- CardiolRxCardiol Therapeutics Inc. · Phase 3
- GoflikiceptR-Pharm International, LLC · Phase 3
- VTX2735Zomagen Biosciences Ltd. · Phase 2
Coming up2
- 31 Dec 2027Phase 2/3 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 31 Dec 2027 | Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387 | |
| Phase 2Recruiting | 31 Dec 2027 | Transition to KPL-387 Monotherapy Dosing & Administration Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026